⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 13, 2024AmyloidOpen Access

Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis

Milou Berends Anne F. Brunger Johan Bijzet Bart‐Jan Kroesen Gea Drost Fiete Lange Charlotte E. Teunissen Sjors in ‘t Veld Alexander F. J. E. Vrancken Rijk O. B. Gans Bouke P. C. Hazenberg Paul A. van der Zwaag Hans Nienhuis

View Full Paper

Ask AI

Bookmark

Share

Abstract

Objective To evaluate serum neurofilament light chain (sNfL) as biomarker of disease onset, progression and treatment effect in hereditary transthyretin (ATTRv) amyloidosis patients and TTR variant (TTRv) carriers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Berends et al. (2024) studied this question.

synapsesocial.com/papers/68e7433fb6db6435876bc1e7 https://doi.org/10.1080/13506129.2024.2327342

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice2024 · 23 citations
2Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis2025 · 4 citations
3Exploratory Evaluation of the Predictive Value of Serum Neurofilament Light Chain for Autonomic Neuropathy in Hereditary Transthyretin AmyloidosisOriginal Research · 2026
4Evaluation of serum neurofilament light chain, GFAP, and peripherin as biomarkers in hereditary transthyretin amyloidosisOriginal Research · 2026 · 1 citations
5Exploring the role of glial fibrillary acid protein and neurofilament light chains in patients with hereditary transthyretin amyloidosis with polyneuropathyRetrospective Study · 2025 · 2 citations